US Cancer Center collects Medical Data for the Evaluation of Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine

Photo by Glenn Carstens-Peters

M.D. Anderson Cancer Center is recruiting patients for the clinical trial of Medical Data Collection for the Evaluation of Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine.

This study collects data on the use of radiofrequency ablation and cement augmentation for the treatment of cancer that has spread to the spine (metastases to the spine). Radiofrequency ablation with cement augmentation is a useful approach for the treatment of secondary metastasis to the spine. Information collected in this study may help doctors to learn the effectiveness of this therapy, and may help to evaluate optimal technique, appropriate patient selection, and management of complications.

Patients who underwent radiofrequency ablation with cement augmentation at the Department of Interventional Radiology at MD Anderson Cancer Center (MDACC) between 1/1/2017 and 9/26/2020 can be enrolled into this research.

The population that are excluded from participation: patients who underwent radiofrequency ablation with cement augmentation at the Department of Interventional Radiology at MD Anderson Cancer Center (MDACC) between 1/1/2017 and 9/26/2020.

Among primary outcome measures are the Technical success and Descriptive statistical analysis will be performed in order to assess technical success, clinical success, and complication rates. Results will be compared with data available from other published literature.

The study will take place at the M D Anderson Cancer Center, Houston, Texas, United States.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04751422